Muscarinic agonists and antagonists in schizophrenia: Recent therapeutic advances and future directions

Amanda R. Bolbecker, Anantha Shekhar

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Citations (Scopus)

Abstract

Existing therapies for schizophrenia have limited efficacy, and significant residual positive, negative, and cognitive symptoms remain in many individuals with the disorder even after treatment with the current arsenal of antipsychotic drugs. Preclinical and clinical data suggest that selective activation of the muscarinic cholinergic system may represent novel therapeutic mechanisms for the treatment of schizophrenia. The therapeutic relevance of earlier muscarinic agonists was limited by their lack of receptor selectivity and adverse event profile arising from activation of nontarget muscarinic receptors. Recent advances in developing compounds that are selective to muscarinic receptor subtypes or activate allosteric receptor sites offer tremendous promise for therapeutic targeting of specific muscarinic receptor subtypes in schizophrenia.

Original languageEnglish
Title of host publicationHandbook of Experimental Pharmacology
Pages167-190
Number of pages24
Volume208
DOIs
StatePublished - 2012

Publication series

NameHandbook of Experimental Pharmacology
Volume208
ISSN (Print)01712004
ISSN (Electronic)18650325

Fingerprint

Muscarinic Agonists
Muscarinic Antagonists
Muscarinic Receptors
Schizophrenia
Cholinergic Agents
Chemical activation
Arsenals
Allosteric Site
Neurobehavioral Manifestations
Antipsychotic Agents
Therapeutics
Direction compound

Keywords

  • Acetylcholine
  • Allosteric
  • Cholinergic
  • Cognitive
  • Muscarinic
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry

Cite this

Bolbecker, A. R., & Shekhar, A. (2012). Muscarinic agonists and antagonists in schizophrenia: Recent therapeutic advances and future directions. In Handbook of Experimental Pharmacology (Vol. 208, pp. 167-190). (Handbook of Experimental Pharmacology; Vol. 208). https://doi.org/10.1007/978-3-642-23274-9_8

Muscarinic agonists and antagonists in schizophrenia : Recent therapeutic advances and future directions. / Bolbecker, Amanda R.; Shekhar, Anantha.

Handbook of Experimental Pharmacology. Vol. 208 2012. p. 167-190 (Handbook of Experimental Pharmacology; Vol. 208).

Research output: Chapter in Book/Report/Conference proceedingChapter

Bolbecker, AR & Shekhar, A 2012, Muscarinic agonists and antagonists in schizophrenia: Recent therapeutic advances and future directions. in Handbook of Experimental Pharmacology. vol. 208, Handbook of Experimental Pharmacology, vol. 208, pp. 167-190. https://doi.org/10.1007/978-3-642-23274-9_8
Bolbecker AR, Shekhar A. Muscarinic agonists and antagonists in schizophrenia: Recent therapeutic advances and future directions. In Handbook of Experimental Pharmacology. Vol. 208. 2012. p. 167-190. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/978-3-642-23274-9_8
Bolbecker, Amanda R. ; Shekhar, Anantha. / Muscarinic agonists and antagonists in schizophrenia : Recent therapeutic advances and future directions. Handbook of Experimental Pharmacology. Vol. 208 2012. pp. 167-190 (Handbook of Experimental Pharmacology).
@inbook{33fb501859df494cb13ce77852e7bf40,
title = "Muscarinic agonists and antagonists in schizophrenia: Recent therapeutic advances and future directions",
abstract = "Existing therapies for schizophrenia have limited efficacy, and significant residual positive, negative, and cognitive symptoms remain in many individuals with the disorder even after treatment with the current arsenal of antipsychotic drugs. Preclinical and clinical data suggest that selective activation of the muscarinic cholinergic system may represent novel therapeutic mechanisms for the treatment of schizophrenia. The therapeutic relevance of earlier muscarinic agonists was limited by their lack of receptor selectivity and adverse event profile arising from activation of nontarget muscarinic receptors. Recent advances in developing compounds that are selective to muscarinic receptor subtypes or activate allosteric receptor sites offer tremendous promise for therapeutic targeting of specific muscarinic receptor subtypes in schizophrenia.",
keywords = "Acetylcholine, Allosteric, Cholinergic, Cognitive, Muscarinic, Psychosis, Schizophrenia",
author = "Bolbecker, {Amanda R.} and Anantha Shekhar",
year = "2012",
doi = "10.1007/978-3-642-23274-9_8",
language = "English",
isbn = "9783642232732",
volume = "208",
series = "Handbook of Experimental Pharmacology",
pages = "167--190",
booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - Muscarinic agonists and antagonists in schizophrenia

T2 - Recent therapeutic advances and future directions

AU - Bolbecker, Amanda R.

AU - Shekhar, Anantha

PY - 2012

Y1 - 2012

N2 - Existing therapies for schizophrenia have limited efficacy, and significant residual positive, negative, and cognitive symptoms remain in many individuals with the disorder even after treatment with the current arsenal of antipsychotic drugs. Preclinical and clinical data suggest that selective activation of the muscarinic cholinergic system may represent novel therapeutic mechanisms for the treatment of schizophrenia. The therapeutic relevance of earlier muscarinic agonists was limited by their lack of receptor selectivity and adverse event profile arising from activation of nontarget muscarinic receptors. Recent advances in developing compounds that are selective to muscarinic receptor subtypes or activate allosteric receptor sites offer tremendous promise for therapeutic targeting of specific muscarinic receptor subtypes in schizophrenia.

AB - Existing therapies for schizophrenia have limited efficacy, and significant residual positive, negative, and cognitive symptoms remain in many individuals with the disorder even after treatment with the current arsenal of antipsychotic drugs. Preclinical and clinical data suggest that selective activation of the muscarinic cholinergic system may represent novel therapeutic mechanisms for the treatment of schizophrenia. The therapeutic relevance of earlier muscarinic agonists was limited by their lack of receptor selectivity and adverse event profile arising from activation of nontarget muscarinic receptors. Recent advances in developing compounds that are selective to muscarinic receptor subtypes or activate allosteric receptor sites offer tremendous promise for therapeutic targeting of specific muscarinic receptor subtypes in schizophrenia.

KW - Acetylcholine

KW - Allosteric

KW - Cholinergic

KW - Cognitive

KW - Muscarinic

KW - Psychosis

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84856645717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856645717&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-23274-9_8

DO - 10.1007/978-3-642-23274-9_8

M3 - Chapter

C2 - 22222699

AN - SCOPUS:84856645717

SN - 9783642232732

VL - 208

T3 - Handbook of Experimental Pharmacology

SP - 167

EP - 190

BT - Handbook of Experimental Pharmacology

ER -